Pattern Pharma’s patent-protected immunotherapeutic, PPI-100, mobilizes innate immunity by targeting TLR4, in order to address the immune failure underpinning cancers. PPI-100 activates dendritic cells and macrophages, increasing antigen-presenting activities directed at tumor antigens and resulting in anti-cancer cytotoxic T-cells and long-term T-cell memory. PPI-100 is being developed in the perioperative setting to address the >40% relapse rate in cancer patients 5 years following surgery, and works with MD Anderson, Massachusetts General Hospital and others.

Event details

Date: January 8 - 10, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


18 in total